AstraZeneca receives FDA complete response letter for paediatric use of Symbicort
This article was originally published in Scrip
AstraZeneca has received a US FDA complete response letter for its combination asthma therapy Symbicort (budesonide plus formoterol fumarate dihydrate) for the long-term maintenance treatment of asthma in paediatric patients aged six to 11 years.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.